Drug Profile
ISIS 5132
Alternative Names: CGP 69846ALatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Protein kinase inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 16 Sep 2002 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
- 16 Sep 2002 Discontinued - Phase-II for Breast cancer in USA (unspecified route)
- 16 Sep 2002 Discontinued - Phase-II for Colorectal cancer in Canada (IV)